LNP023

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia4
62Paroxysmal nocturnal hemoglobinuria31
66IgA nephropathy35
IDDisease name (Link within this page)Number of trials
109Atypical hemolytic uremic syndrome5
222Primary nephrotic syndrome14

61. Autoimmune hemolytic anemia


Clinical trials : 183Drugs : 119 - (DrugBank : 42) / Drug target genes : 31 - Drug target pathways : 156 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 358Drugs : 160 - (DrugBank : 35) / Drug target genes : 33 - Drug target pathways : 116 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 349Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

109. Atypical hemolytic uremic syndrome


Clinical trials : 123Drugs : 29 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 11 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 382Drugs : 278 - (DrugBank : 98) / Drug target genes : 73 - Drug target pathways : 197 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries